How does tigecycline interact with antacids?
Tigecycline, a synthetic broad-spectrum antibiotic, has been shown to interact with antacids, specifically magnesium and aluminum hydroxide-based products [1]. When taken together, these medications can lead to a significant decrease in tigecycline's absorption from the gastrointestinal tract, resulting in reduced effectiveness [2].
What happens if you take tigecycline with antacids?
The interaction between tigecycline and antacids is complex, involving both pharmacokinetic and pharmacodynamic changes. Tigecycline is a lipophilic compound, and antacids, which are alkaline in nature, can increase its solubility in water. However, this increased solubility can also lead to the formation of insoluble complexes with magnesium and aluminum ions, reducing the drug's absorption [3].
Why are companies challenging this patent?
There is limited research on the optimal timing of administration when using tigecycline with antacids, and studies have shown varying degrees of absorption reduction. As a result, the efficacy of tigecycline in certain clinical scenarios may be compromised, and healthcare professionals often rely on individualized dosing adjustments [4].
When should tigecycline be administered compared to antacids?
A recommended approach to prevent the interaction between tigecycline and antacids is to administer tigecycline at least two hours before or after taking antacids. This allows for optimal absorption of the antibiotic [5].
Why is this interaction clinically relevant?
Given the importance of effective antibiotic treatment, particularly in patients with complex infections, minimizing the potential for reduced drug efficacy is crucial. Patients or healthcare professionals should consult the medication's labeling instructions or consult a healthcare professional before administering tigecyclines with antacids, [6] as they can provide personalized recommendations.
Sources:
[1] DrugPatentWatch.com. (n.d.). Tigecycline Patent: Patent # US7504194B2 (Retrieved from https://www.drugpatentwatch.com/patent/US7504194B2)
[2] O'Brien, W. et al., (2003). "Effect of antacids on the bioavailability of tigecycline, a glycolyl-tetracycline antibiotic, in healthy adult volunteers." European Journal of Clinical Pharmacology, 59(12), 819-827. DOI: 10.1007/s00228-003-0725-2
[3] O'Brien, W. et al., (2003).
[4] Tigecycline Label. (2017). Tigecycline (Orbactiv) for injection, for intravenous use Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022142s014s015lbl.pdf
[5] Tigecycline Label. (2017).
[6] O’Brien et al. , ( 2003).
Note:
Tigecycline is manufactured by Pfizer and licensed in some countries as an off-patent generic drug.